Maravai LifeSciences Holdings, Inc. (MRVI)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
7.68 USD
-0.69
(-8.244%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.79 +0.11 (1.405%) ⇧ (Aug. 28, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:05 a.m. EDT
The investment case for Maravai LifeSciences is currently broken by a catastrophic multi-year price collapse and deteriorating fundamentals. The stock has lost nearly 96% of its value over the last four years, with every single year showing negative returns, signaling a persistent failure in the market's valuation of the business. While recent headlines mention revenue beats and patent wins, these operational improvements have failed to arrest the bleeding stock price, which remains trapped near its 52-week lows despite a recent volatile spike. The balance sheet is fragile, carrying significant debt against negative free cash flow and negative equity returns, making it a value trap where the low price reflects genuine structural issues rather than a bargain. With no dividend to provide income and a technical structure dominated by heavy put option positioning anticipating further drops, the outlook is severely bearish. Investors should avoid this security until there is clear, sustained evidence that the business can generate positive cash flow and reverse the long-term decline. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.100113 |
| MSTL | 0.111225 |
| AutoETS | 0.112012 |
| AutoTheta | 0.118996 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 12.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.112 |
| Excess Kurtosis | -0.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 61.335 |
| Revenue per Share | 1.429 |
| Market Cap | 2,844,347,136 |
| Forward P/E | -76.50 |
| Beta | 0.58 |
| Profit Margins | -37.07% |
| Website | https://www.maravai.com |
As of Aug. 22, 2026, 5:05 a.m. EDT: Speculators are overwhelmingly positioned for downside protection, with massive open interest in deep out-of-the-money puts relative to negligible call volume. The distribution of put options shows heavy concentration at strikes significantly below the current price, indicating a consensus expectation of further decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.5316455 |
| Address1 | 10,770 Wateridge Circle |
| Address2 | Suite 200 |
| All Time High | 63.55 |
| All Time Low | 1.665 |
| Ask | 10.13 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 6,528,980 |
| Average Daily Volume3 Month | 3,458,009 |
| Average Volume | 3,458,009 |
| Average Volume10Days | 6,528,980 |
| Beta | 0.582 |
| Bid | 7.64 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.374 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.68 |
| Current Ratio | 4.052 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.175 |
| Day Low | 7.65 |
| Debt To Equity | 61.335 |
| Display Name | Maravai LifeSciences |
| Earnings Call Timestamp End | 1,786,050,000 |
| Earnings Call Timestamp Start | 1,786,050,000 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -19,745,000 |
| Ebitda Margins | -0.09458 |
| Enterprise To Ebitda | -73.093 |
| Enterprise To Revenue | 6.913 |
| Enterprise Value | 1,443,213,696 |
| Eps Current Year | -0.18077 |
| Eps Forward | -0.10039 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.549 |
| Fifty Day Average Change | 1.131 |
| Fifty Day Average Change Percent | 0.17269814 |
| Fifty Two Week Change Percent | 253.16455 |
| Fifty Two Week High | 9.42 |
| Fifty Two Week High Change | -1.7400002 |
| Fifty Two Week High Change Percent | -0.1847134 |
| Fifty Two Week Low | 2.285 |
| Fifty Two Week Low Change | 5.3949995 |
| Fifty Two Week Low Change Percent | 2.3610501 |
| Fifty Two Week Range | 2.285 - 9.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,605,882,600,000 |
| Float Shares | 114,248,163 |
| Forward Eps | -0.10039 |
| Forward P E | -76.50164 |
| Free Cashflow | -3,623,125 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 415 |
| Fullday Change | -0.69 |
| Fullday Change Percent | -8.24373 |
| Fullday Price | 7.7879 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.35707 |
| Gross Profits | 74,548,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07274 |
| Held Percent Institutions | 0.96629995 |
| Implied Shares Outstanding | 370,357,705 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-11-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California. |
| Long Name | Maravai LifeSciences Holdings, Inc. |
| Market | us_market |
| Market Cap | 2,844,347,136 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_573282023 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -77,386,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,244,807,648 |
| Number Of Analyst Opinions | 5 |
| Open | 8.12 |
| Operating Cashflow | -25,261,000 |
| Operating Margins | -0.29396 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 858 546 0004 |
| Post Market Change | 0.10790014 |
| Post Market Change Percent | 1.4049498 |
| Post Market Price | 7.7879 |
| Post Market Time | 1,787,960,797 |
| Previous Close | 8.37 |
| Price Eps Current Year | -42.484924 |
| Price Hint | 2 |
| Price To Book | 5.5895195 |
| Price To Sales Trailing12 Months | 13.623982 |
| Profit Margins | -0.37067002 |
| Quick Ratio | 2.635 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | -0.69 |
| Regular Market Change Percent | -8.24373 |
| Regular Market Day High | 8.175 |
| Regular Market Day Low | 7.65 |
| Regular Market Day Range | 7.65 - 8.175 |
| Regular Market Open | 8.12 |
| Regular Market Previous Close | 8.37 |
| Regular Market Price | 7.68 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 5,562,634 |
| Return On Assets | -0.05708 |
| Return On Equity | -0.33046 |
| Revenue Growth | 0.085 |
| Revenue Per Share | 1.429 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 148,989,545 |
| Shares Percent Shares Out | 0.063 |
| Shares Short | 9,382,604 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,271,035 |
| Short Name | Maravai LifeSciences Holdings, |
| Short Percent Of Float | 0.0746 |
| Short Ratio | 3.73 |
| Source Interval | 15 |
| State | CA |
| Symbol | MRVI |
| Target High Price | 8.0 |
| Target Low Price | 6.5 |
| Target Mean Price | 7.3 |
| Target Median Price | 7.0 |
| Total Cash | 70,091,000 |
| Total Cash Per Share | 0.47 |
| Total Debt | 218,099,008 |
| Total Revenue | 208,775,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.3796 |
| Two Hundred Day Average Change | 3.3003998 |
| Two Hundred Day Average Change Percent | 0.75358474 |
| Type Disp | Equity |
| Volume | 5,562,634 |
| Website | https://www.maravai.com |
| Zip | 92,121 |